You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
重藥控股(000950.SZ):子公司擬5955萬元收購長聖醫藥51%股權
格隆匯 11-04 20:17

格隆匯 11 月 4日丨重藥控股(000950.SZ)公佈,公司下屬控股子公司重慶醫藥(集團)股份有限公司(“重藥股份”)於2020年11月3日,與天聖製藥集團股份有限公司(“天聖製藥”)簽訂《天聖製藥集團股份有限公司重慶醫藥(集團)股份有限公司關於重慶長聖醫藥有限公司之股權轉讓合同》(“股權轉讓合同”),約定重藥股份以5955萬元購買天聖製藥所持重慶長聖醫藥有限公司(“長聖醫藥”)51%股權(不含重慶天聖藥業有限公司位於萬州區天子路214號的建築面積330㎡的辦公樓,下同)。

根據商務部發布的《2019年藥品流通行業運行統計分析報告》顯示藥品流通行業發展趨勢為行業併購重組更趨穩健,強強聯合成為主流。近兩年,國內醫藥流通市場併購重組呈現新的特點,主要是全國性企業併購區域龍頭企業,擴大規模,提高市場份額,區域龍頭企業間強強聯合,優勢互補。

根據整體發展規劃,未來三年,重藥股份將實現各業態、各細分市場的協同發展,着力發展全國市場,打造“橫向最寬,縱向最深”的全國銷售網絡,在已佈局網絡的市場精耕細作,整合區域力量,發揮協同效應,實現各業態的三級配送,成為具有西部帶動力、全國影響力的現代營銷服務型醫藥產業健康集團,力爭進入全國排名前五的醫藥流通配送公司。

長聖醫藥的業務與重藥股份在重慶區縣業務覆蓋區域有重疊,且在部分區縣銷售比重藥股份好,2019年度實現合併營業收入約12.29億元,收購後可與重藥股份資源互補,產生疊加效應,進一步提升在各區縣的市場份額。本項目可提高重藥股份醫藥商業整體業務規模,提升競爭實力。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account